Given the success of approved CAR-T cell therapies, such as KYMRIAH®, YESCARTA®, TECARTUS® and BREYANZI®, this upcoming class of biologics are anticipated to carve out a significant share of the multi-billion dollar cancer immunotherapy market   Roots Analysis has announced the addition of “CAR-T Cell Therapies Market (3rd Edition) by Target Indications (NHL, Multiple...